Credit Suisse AG Decreases Position in AtriCure Inc. (ATRC)

Credit Suisse AG lowered its stake in AtriCure Inc. (NASDAQ:ATRC) by 39.0% during the third quarter, Holdings Channel reports. The institutional investor owned 16,605 shares of the medical device company’s stock after selling 10,638 shares during the period. Credit Suisse AG’s holdings in AtriCure were worth $581,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new position in AtriCure in the 3rd quarter valued at about $521,000. BlueMountain Capital Management LLC grew its stake in AtriCure by 121.8% in the 2nd quarter. BlueMountain Capital Management LLC now owns 14,904 shares of the medical device company’s stock valued at $403,000 after buying an additional 8,184 shares during the last quarter. Campbell & CO Investment Adviser LLC grew its stake in AtriCure by 37.7% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 15,339 shares of the medical device company’s stock valued at $537,000 after buying an additional 4,200 shares during the last quarter. AMS Capital Ltda acquired a new position in AtriCure in the 3rd quarter valued at about $725,000. Finally, JPMorgan Chase & Co. grew its stake in AtriCure by 225.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,187 shares of the medical device company’s stock valued at $777,000 after buying an additional 15,378 shares during the last quarter. Institutional investors and hedge funds own 81.70% of the company’s stock.

ATRC has been the topic of a number of research reports. Needham & Company LLC upped their price target on shares of AtriCure from $36.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, October 4th. Canaccord Genuity upped their price target on shares of AtriCure from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research lowered shares of AtriCure from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Finally, BidaskClub lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 13th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. AtriCure has a consensus rating of “Buy” and an average target price of $35.20.

Shares of NASDAQ:ATRC opened at $29.84 on Friday. AtriCure Inc. has a 12-month low of $14.88 and a 12-month high of $36.49. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -35.95 and a beta of 0.22. The company has a current ratio of 2.62, a quick ratio of 1.96 and a debt-to-equity ratio of 0.31.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, November 1st. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). AtriCure had a negative return on equity of 16.92% and a negative net margin of 10.41%. The business had revenue of $49.90 million for the quarter, compared to analyst estimates of $49.90 million. During the same quarter in the previous year, the company earned ($0.22) EPS. The business’s revenue for the quarter was up 18.2% on a year-over-year basis. Equities analysts expect that AtriCure Inc. will post -0.9 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2019/01/12/credit-suisse-ag-decreases-position-in-atricure-inc-atrc.html.

AtriCure Company Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Further Reading: Day Trading – Risk Worth the Reward?

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply